Enigma Diagnostics Ltd, a point-of-care molecular diagnostics company, signed a preliminary agreement for two licenses with Roche Molecular Systems, Inc. The licenses will provide Salisbury, UK-based Enigma full access to practice HybProbe real-time polymerase chain reaction (PCR) chemistry, and will allow the company to commercialise diagnostics for human and veterinary applications on a worldwide basis. This complements Enigma’s existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is a spin-out from the UK government’s chemical and biological weapons research centre at Porton Down. The company is currently developing a series of assays for infectious diseases including chlamydia, influenza and methicillin-resistant Staphylococcus aureus (MRSA). These tests will be combined with Enigma’s real-time PCR system to enable one-step molecular testing at point of care.
Financial terms of the Roche licenses were not disclosed.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
